Analysis: We need to do for TB vaccines what we’ve done for COVID-19

Analysis: We need to do for TB vaccines what we’ve done for COVID-19

It is little wonder that some TB vaccine researchers suffer from a rare syndrome that understandably threatens their mental health. Symptoms include frustration, impatience, irritability, seemingly inexplicable rage, and in the least resilient, despair. It’s called VJS or vaccine jealousy syndrome, writes Chris Bateman.

Read More

XACT III: A trial asking how to take TB tests to the people

XACT III: A trial asking how to take TB tests to the people

Roughly two in five people newly ill with TB worldwide are never diagnosed. In South Africa, this amounts to about 120 000 to 160 000 people per year. A large new study called XACT III is testing ways in which more people can be diagnosed and started on TB treatment more quickly. Tiyese Jeranji reports.

Read More

After setbacks, rollout of new TB prevention pills to start in six districts

After setbacks, rollout of new TB prevention pills to start in six districts

After various delays and setbacks, a new, less toxic, short-course tuberculosis preventive therapy called 3HP is finally being launched in six districts in South Africa. Tiyese Jeranji reports.

Read More

400 people in SA with highly drug-resistant TB to get new three-drug regimen

400 people in SA with highly drug-resistant TB to get new three-drug regimen

Treating highly drug-resistant forms of tuberculosis can take anything from nine to 24 months and patients have to contend with various unpleasant, and sometimes dangerous, side effects. A new six-month regimen made up of just three drugs that will be offered to 400 patients in South Africa might offer a better solution for some. Tiyese Jeranji reports.

Read More